Travere Therapeutics (TVTX) Profit After Tax (2011 - 2026)
Travere Therapeutics posted quarterly Profit After Tax of -$37.1 million for Q1 2026, up 10.0% year-on-year from -$33.7 million in Q1 2025, and down 68.75% on a QoQ basis from -$22.0 million in Q4 2025.
Travere Therapeutics (TVTX) has 16 years of Profit After Tax data on file, last reported at -$37.1 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 10.0% year-over-year to -$37.1 million; the trailing twelve-month figure through Mar 2026 stood at -$46.1 million (up 79.64% YoY), and the FY2025 full-year result was -$50.3 million, up 84.32% from the prior year.
- Profit After Tax for Q1 2026 stood at -$37.1 million, down from -$22.0 million in the prior quarter.
- Across five years, Profit After Tax topped out at $150.7 million in Q3 2023 and bottomed at -$136.1 million in Q1 2024.
- The 5-year median for Profit After Tax is -$67.0 million (2022), against an average of -$50.3 million.
- The widest annual swing landed in 2023, when Profit After Tax soared 279.31%; it then slumped 136.32% in 2024.
- A 5-year view of Profit After Tax shows it stood at -$85.6 million in 2022, then decreased by 5.3% to -$90.2 million in 2023, then surged by 33.16% to -$60.3 million in 2024, then soared by 63.52% to -$22.0 million in 2025, then tumbled by 68.75% to -$37.1 million in 2026.
- The last three Profit After Tax figures came in at -$37.1 million (Q1 2026), -$22.0 million (Q4 2025), and $25.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | -37.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.10 Mn |
| Dec 31, 2025 | -21.99 Mn |
| Sep 30, 2025 | 25.71 Mn |
| Jun 30, 2025 | -12.76 Mn |
| Mar 31, 2025 | -41.23 Mn |
| Dec 31, 2024 | -60.27 Mn |
| Sep 30, 2024 | -54.75 Mn |
| Jun 30, 2024 | -70.41 Mn |
| Mar 31, 2024 | -136.06 Mn |
| Dec 31, 2023 | -90.17 Mn |
| Sep 30, 2023 | 150.74 Mn |
| Jun 30, 2023 | -101.93 Mn |
| Mar 31, 2023 | -86.33 Mn |
| Dec 31, 2022 | -85.64 Mn |
| Sep 30, 2022 | -84.06 Mn |
| Jun 30, 2022 | -67.03 Mn |
| Mar 31, 2022 | -81.75 Mn |
| Dec 31, 2021 | -51.57 Mn |
| Sep 30, 2021 | -35.64 Mn |
| Jun 30, 2021 | -39.01 Mn |
| Mar 31, 2021 | -53.87 Mn |
| Dec 31, 2020 | -121.62 Mn |
| Sep 30, 2020 | -22.55 Mn |
| Jun 30, 2020 | -26.07 Mn |
| Mar 31, 2020 | 808,000.00 |
| Dec 31, 2019 | -30.26 Mn |
| Sep 30, 2019 | -36.49 Mn |
| Jun 30, 2019 | -38.70 Mn |
| Mar 31, 2019 | -40.98 Mn |
| Dec 31, 2018 | -7.46 Mn |
| Sep 30, 2018 | -54.52 Mn |
| Jun 30, 2018 | -22.33 Mn |
| Mar 31, 2018 | -18.38 Mn |
| Dec 31, 2017 | -17.62 Mn |
| Sep 30, 2017 | -17.79 Mn |
| Jun 30, 2017 | -13.23 Mn |
| Mar 31, 2017 | -11.09 Mn |
| Dec 31, 2016 | -8.60 Mn |
| Sep 30, 2016 | -37.11 Mn |
| Jun 30, 2016 | -13.40 Mn |
| Mar 31, 2016 | 11.22 Mn |
| Dec 31, 2015 | -2.47 Mn |
| Sep 30, 2015 | 105.58 Mn |
| Jun 30, 2015 | -25.53 Mn |
| Mar 31, 2015 | 39.66 Mn |
| Dec 31, 2014 | -29.03 Mn |
| Sep 30, 2014 | -17.98 Mn |
| Jun 30, 2014 | 11.81 Mn |
| Mar 31, 2014 | -75.74 Mn |
| Dec 31, 2013 | -12.59 Mn |
| Sep 30, 2013 | -12.01 Mn |
| Jun 30, 2013 | -5.15 Mn |
| Mar 31, 2013 | -4.74 Mn |
| Nov 30, 2012 | -3,661.00 |
| Aug 31, 2012 | -0.03 |
| May 31, 2012 | -3,509.00 |
| Nov 30, 2011 | -3,518.00 |
| Aug 31, 2011 | -3,525.00 |
| Feb 28, 2011 | 18,941.78 |